Analysis of immune check point of musculoskeltal tumor
| Project/Area Number |
15K19993
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Orthopaedic surgery
|
|---|
| Research Institution | Mie University |
|---|
Principal Investigator |
TAKUYA KAKIMOTO 三重大学, 医学系研究科, リサーチアソシエイト (50741162)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2017: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | soft tissue sarcoma / cancer testis antigen / NY-ESO-1 / MAGE-A4 / PD-L1 / 軟部肉腫 / PD-1 |
|---|
| Outline of Final Research Achievements |
Immune check point such as Cancer testis antigens (CTA) have emerged over the last decade as both a diagnostic marker and a therapeutic target in malignant lesions. Recently, aberrant expression of PD-1, PD-L1, NY-ESO-1 and MAGE-A4 has been reported in a variety of neoplasms. However, there is only a limited report about those expression in high grade sarcoma. The purpose of this study is to examine those expression in high-grade soft tissue sarcomas and to evaluate the relationship between CTA expression and the various clinicopathological features. In this study, it was found that PD-L1 was expressed in soft tissue tumors and the NY-ESO-1 was expressed in more than half of samples of synovial sarcoma patients. The 5-years-overall survival rates were significantly higher in high grade sarcoma patients with NY-ESO-1 positive tumors than in those with NY-ESO-1 negative. Furthermore, we showed the MAGE-A4 was expressed only in more than half of synovial sarcoma patients.
|
Report
(4 results)
Research Products
(30 results)
-
-
-
[Journal Article] STAT3 inhibitor, cucurbitacin I, is a novel therapeutic agent for osteosarcoma.2016
Author(s)
Oi T, Asanuma K, Matsumine A, Matsubara T, Nakamura T, Iino T, Asanuma Y, Goto M, Okuno K, Kakimoto T, Yada Y, Sudo A
-
Journal Title
Int J Oncol
Volume: 49(6)
Issue: 6
Pages: 2275-2284
DOI
Related Report
Peer Reviewed
-
[Journal Article] Minimally invasive surgery using intraoperative electron-beam radiotherapy for the treatment of soft tissue sarcoma of the extremities with tendon involvement.2016
Author(s)
Matsumine A, Tsujii M, Nakamura T, Asanuma K, Matsubara T, Kakimoto T, Yada Y, Takada A, Ii N, Nomoto Y, Sudo A
-
Journal Title
World J Surg Oncol
Volume: 14(1)
Issue: 1
Pages: 214-214
DOI
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
